GlassScriptPhysician profile
Christian E Machado
NPI 1780667246
$24,736.37
in general payments reported to CMS, 2019-2025
26 companies · $1,375 in 2025
The $1,375 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $402 · 2021: $1,054 · 2022: $1,951 · 2023: $894 · 2024: $2,557 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398 · Travel and Lodging: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.33 |
| Travel and Lodging | $1,428.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22,154.59 | 2019-2025 | Aveir, Amplatzer Amulet, Ensite |
| Novartis Pharmaceuticals Corporation | $330.22 | 2019-2025 | |
| Boston Scientific Corporation | $255.74 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $218.86 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $209.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $186.70 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $175.46 | 2019-2023 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.13 | 2019 | |
| Heartflow, INC. | $157.04 | 2019 | |
| Philips North America LLC | $152.78 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $113.16 | 2022-2025 | Assure Wcd |
| Pfizer INC. | $102.00 | 2024-2025 | |
| Siemens Medical Solutions USA, INC. | $98.17 | 2019-2020 | |
| Medtronic, INC. | $79.08 | 2023-2025 | Symplicity G3, In.Pact Admiral |
| Janssen Pharmaceuticals, INC | $50.61 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $50.25 | 2023 | Optimizer |
| Cordis US Corp. | $40.72 | 2025 | Mynx Control Venous |
| Lundbeck LLC | $31.49 | 2019 | |
| Amgen INC. | $27.53 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $27.16 | 2019 | |
| Bridgebio Pharma, INC. | $23.31 | 2025 | Attruby |
| Elutia, INC. | $23.27 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $21.35 | 2023 | Inpefa |
| Ge Healthcare | $18.17 | 2025 | |
| Astellas Pharma US INC | $17.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.71 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Machado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.